Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 Feb;62(2):127–132. doi: 10.1136/ard.62.2.127

Assessment of enthesitis in ankylosing spondylitis

L Heuft-Dorenbosch 1, A Spoorenberg 1, A van Tubergen 1, R Landewe 1, H van der Tempel 1, H Mielants 1, M Dougados 1, D van der Heijde 1
PMCID: PMC1754445  PMID: 12525381

Abstract

Objective: To assess, firstly, the validity of the enthesis index published by Mander (Mander enthesis index (MEI)) and, secondly, to investigate whether it is possible to define a new enthesis index that is less time consuming to perform with at least similar or better properties.

Methods: Data from the OASIS cohort, an international, longitudinal, observational study on outcome in ankylosing spondylitis, were used. In this study, measures of disease activity, including the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the MEI, were assessed regularly in 217 patients. With the MEI, for each measurement period independently, a process of data reduction was performed to identify the entheses most commonly reported as painful by the patients. A more concise enthesis index was constructed with aid of the entheses found in this way. Correlations with measures of disease activity were used to test the validity of several entheses indices.

Results: Reduction of the number of entheses from 66 to 13 and omitting grading of the intensity of pain resulted in an index which was named the "Maastricht Ankylosing Spondylitis Enthesitis Score" (MASES). The MASES (range 0–13) has much greater feasibility than the MEI (range 0–90). However, up to 21% of patients with a score >0 on the MEI were not identified by a score on the MASES >0. Only 2.1% of the patients with an original enthesis score >0 had an original score on the MEI >3 (range 0–90) and it can be questioned whether a low score on the MEI index represents clinically important enthesitis. The Spearman correlation coefficient between the MASES score and the MEI was 0.90 and between the MASES and the BASDAI was 0.53 compared with a correlation of 0.59 between the MEI and the BASDAI.

Conclusions: MASES seems to be a good alternative to the MEI with much better feasibility.

Full Text

The Full Text of this article is available as a PDF (155.5 KB).

graphic file with name ar0297.f1.jpg

Open in a new tab

Mander enthesis index. Reproduced with permission of the authors and the copyright holders from reference 3. Copyright @ 1987 Annals of the Rheumatic Disease.

Figure 2.

Figure 2

Open in a new tab

MASES.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ball J. Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis. 1971 May;30(3):213–223. doi: 10.1136/ard.30.3.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Boers M., Brooks P., Strand C. V., Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol. 1998 Feb;25(2):198–199. [PubMed] [Google Scholar]
  3. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., Gromnica-Ihle E., Kellner H., Krause A., Schneider M. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002 Apr 6;359(9313):1187–1193. doi: 10.1016/s0140-6736(02)08215-6. [DOI] [PubMed] [Google Scholar]
  4. Calin A., Nakache J. P., Gueguen A., Zeidler H., Mielants H., Dougados M. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) 1999 Sep;38(9):878–882. doi: 10.1093/rheumatology/38.9.878. [DOI] [PubMed] [Google Scholar]
  5. Dougados M., Béhier J. M., Jolchine I., Calin A., van der Heijde D., Olivieri I., Zeidler H., Herman H. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum. 2001 Jan;44(1):180–185. doi: 10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  6. Dougados M., Gueguen A., Nakache J. P., Velicitat P., Veys E. M., Zeidler H., Calin A. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) 1999 Mar;38(3):235–244. doi: 10.1093/rheumatology/38.3.235. [DOI] [PubMed] [Google Scholar]
  7. Garrett S., Jenkinson T., Kennedy L. G., Whitelock H., Gaisford P., Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994 Dec;21(12):2286–2291. [PubMed] [Google Scholar]
  8. Gerster J. C. Plantar fasciitis and Achilles tendinitis among 150 cases of seronegative spondarthritis. Rheumatol Rehabil. 1980 Nov;19(4):218–222. doi: 10.1093/rheumatology/19.4.218. [DOI] [PubMed] [Google Scholar]
  9. Jones S. D., Calin A., Steiner A. An update on the Bath Ankylosing Spondylitis Disease Activity and Functional Indices (BASDAI, BASFI): excellent Cronbach's alpha scores. J Rheumatol. 1996 Feb;23(2):407–407. [PubMed] [Google Scholar]
  10. Lehtinen A., Taavitsainen M., Leirisalo-Repo M. Sonographic analysis of enthesopathy in the lower extremities of patients with spondylarthropathy. Clin Exp Rheumatol. 1994 Mar-Apr;12(2):143–148. [PubMed] [Google Scholar]
  11. Mander M., Simpson J. M., McLellan A., Walker D., Goodacre J. A., Dick W. C. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis. 1987 Mar;46(3):197–202. doi: 10.1136/ard.46.3.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Marzo-Ortega H., McGonagle D., O'Connor P., Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum. 2001 Sep;44(9):2112–2117. doi: 10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  13. McGonagle D., Gibbon W., Emery P. Classification of inflammatory arthritis by enthesitis. Lancet. 1998 Oct 3;352(9134):1137–1140. doi: 10.1016/S0140-6736(97)12004-9. [DOI] [PubMed] [Google Scholar]
  14. McGonagle D., Khan M. A., Marzo-Ortega H., O'Connor P., Gibbon W., Emery P. Enthesitis in spondyloarthropathy. Curr Opin Rheumatol. 1999 Jul;11(4):244–250. doi: 10.1097/00002281-199907000-00004. [DOI] [PubMed] [Google Scholar]
  15. Prevoo M. L., van Riel P. L., van 't Hof M. A., van Rijswijk M. H., van Leeuwen M. A., Kuper H. H., van de Putte L. B. Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis. Br J Rheumatol. 1993 Jul;32(7):589–594. doi: 10.1093/rheumatology/32.7.589. [DOI] [PubMed] [Google Scholar]
  16. Spoorenberg A., van der Heijde D., de Klerk E., Dougados M., de Vlam K., Mielants H., van der Tempel H., van der Linden S. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol. 1999 Apr;26(4):980–984. [PubMed] [Google Scholar]
  17. van der Heijde D., Bellamy N., Calin A., Dougados M., Khan M. A., van der Linden S. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol. 1997 Nov;24(11):2225–2229. [PubMed] [Google Scholar]
  18. van der Heijde D., van der Linden S., Bellamy N., Calin A., Dougados M., Khan M. A. Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. J Rheumatol. 1999 Apr;26(4):945–947. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES